The Burrill Report

The Burrill Report (January 13, 2014): Big Pharma Faces Tougher M&A Landscape (.MP3,14.57 Mb)

The world’s biggest pharmaceutical companies laid low on the M&A front in 2013 with biotech and specialty pharmaceuticals making headlines with acquisitions. The rising stock market suggests a tougher time ahead for Big Pharma as likely targets have grown more expensive and competitors for assets have grown stronger. We spoke to Jeff Greene, EY's global life sciences transaction advisory leader, about his firm’s recent report on Big Pharma M&A, how despite new drug approvals they are losing market share, and why, even with their rising market caps, they are in a worse position to do deals today.

January 10, 2014
http://www.burrillreport.com/article-big_pharma_faces_tougher_ma_landscape.html